Compare Atlassian Corporation PLC (TEAM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs Zimmer Biomet Holdings Inc — how do they compare? Atlassian Corporation PLC trades at $152.52 (market cap $39.10B), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.55B). The key difference: Atlassian Corporation PLC is far larger — about 2.1× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| TEAM | ZBH | |
|---|---|---|
Market Cap | $39.10B | $18.55B |
Sector | Technology | Health |
52-Week High | $182.36 | $107.71 |
52-Week Low | $57.15 | $79.58 |
Enterprise Value | $39.09B | $25.61B |
Dividend Yield | — | 0.99% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
